Pharmaceuticals

Bevacizumab Biosimilars Market Expansion Outlook: $2.23 Billion by 2029 Forecast

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Bevacizumab Biosimilars Market From 2025 To 2034?

The bevacizumab biosimilars market has experienced robust expansion in recent years. It is anticipated to grow from $1.53 billion in 2024 to $1.64 billion in 2025, at a compound annual growth rate (CAGR) of 7.2%. This historical growth can be attributed to elements such as patent expiry, efforts to contain healthcare costs, a rising incidence of cancer, strong market competitiveness, improved patient access and affordability, and the increasing acceptance of biosimilars.

The bevacizumab biosimilars market size is anticipated to experience substantial expansion over the next few years. It is projected to grow to $2.23 billion in 2029, achieving a compound annual growth rate (CAGR) of 7.9%. This projected growth can be attributed to an increasing demand for cancer therapies, expertise in biosimilar development, pressures within healthcare systems, the regulatory landscape for biosimilars, and biosimilar interchangeability. Prominent trends expected during this forecast period involve collaborations and partnerships, advancements and approvals in regulations, continued biosimilar development and innovation, market access strategies, and the comprehensive management of the biosimilar lifecycle.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Are The Main Drivers Boosting The Bevacizumab Biosimilars Industry’s Expansion?

The growing incidence of cancer is anticipated to fuel the expansion of the bevacizumab biosimilar market in the foreseeable future. Cancer incidence is defined as the total number of new cancer cases identified within a particular population over a specified timeframe. Bevacizumab acts as a biologic that obstructs tumor angiogenesis, which can lead to the shrinking and inhibited growth of tumors. It exhibits comparable effectiveness and safety to existing reference biologics in the management of advanced non-small cell lung cancer or metastatic colorectal cancer patients. For example, in October 2024, the UK’s National Health Service (NHS) documented 346,217 new cancer diagnoses in 2022, which translates to an average of 948 cases daily. This indicates a 5% surge compared to the 329,664 diagnoses recorded in 2021. Moreover, cancer diagnoses experienced a 7% uptick, rising from 167,917 to 180,877 in 2022. Thus, the escalating prevalence of cancer cases is a key driver for the bevacizumab biosimilars market.

What Are The Major Segments Identified In The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

What Long-Term Trends Will Shape The Future Growth Of The Bevacizumab Biosimilars Industry?

Product innovation has become a pivotal and increasingly favored trend within the bevacizumab biosimilars market. Prominent market participants are directing their efforts toward developing inventive products to solidify their presence. For example, in May 2022, Viatris, a US-based pharmaceutical company, and Biocon Biologics, also a US-based pharmaceutical company, introduced Abevmy (bevacizumab), a biosimilar akin to Roche’s Avastin (bevacizumab). Abevmy secured approval from Health Canada for application across four distinct oncology indications. This product delivers similar efficacy, safety, and quality to its reference biologic, given its nature as a synthesized humanized monoclonal antibody (MA) that effectively binds to and neutralizes the biological function of human vascular endothelial growth factor (VEGF).

Which Key Players Are Driving Competition In The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Bevacizumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2025, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Filgrastim Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795